Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

摘要: The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process translational research, is critical milestone for non-small-cell lung cancer treatment. Currently, inhibitors are recommended as first-line therapy patients harboring receptor-sensitive mutations. status mutation widely acknowledged superior to other clinical factors, such smoking, gender, and histological types predicting the response inhibitors. However, recent studies have shown that efficacy might differ in with same mutations, highlighting need investigate putative factors related This article reviews associated first-generation gefitinib erlotinib, analyzes their potential implications respect application. In addition, new findings practice were summarized this article.